Search

Your search keyword '"Kido, Ryo"' showing total 218 results
Start Over Author "Kido, Ryo"
218 results on '"Kido, Ryo"'

6. TRANSLATIONAL CKD RESEARCH

Author

Yazawa, Masahiko, Kido, Ryo, Kimura, Kenjiro, Ohira, Seiji, Hasegawa, Takeshi, Hanafusa, Norio, Iseki, Kunitoshi, Tsubakihara, Yoshiharu, and Shibagaki, Yugo

Published
2014

7. Fabry Disease on Peritoneal Dialysis with Cardiac Involvement

Author

Koga-Kobori, Sayako, primary, Sawa, Naoki, additional, Kido, Ryo, additional, Sekine, Akinari, additional, Mizuno, Hiroki, additional, Yamanouchi, Masayuki, additional, Hayami, Noriko, additional, Suwabe, Tatsuya, additional, Hoshino, Junichi, additional, Kinowaki, Keiichi, additional, Ohashi, Kenichi, additional, Fujii, Takeshi, additional, and Ubara, Yoshifumi, additional

Published
2021
Full Text
View/download PDF

11. Lower Diastolic Blood Pressure was Associated with Higher Incidence of Chronic Kidney Disease in the General Population Only in those Using Antihypertensive Medications

Author

Uchida, Daisuke, primary, Kido, Ryo, additional, Kawarazaki, Hiroo, additional, Murasawa, Masaru, additional, Ando, Ayami, additional, Fujimoto, Shouichi, additional, Iseki, Kunitoshi, additional, Moriyama, Toshiki, additional, Yamagata, Kunihiro, additional, Tsuruya, Kazuhiko, additional, Konta, Tsuneo, additional, Narita, Ichiei, additional, Kondo, Masahide, additional, Kasahara, Masato, additional, Asahi, Koichi, additional, Watanabe, Tsuyoshi, additional, and Shibagaki, Yugo, additional

Published
2019
Full Text
View/download PDF

13. Interactive Effectiveness of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers or Their Combination on Survival of Hemodialysis Patients

Author

30238505, Kido, Ryo, Akizawa, Tadao, Fukagawa, Masafumi, Onishi, Yoshihiro, Yamaguchi, Takuhiro, Fukuhara, Shunichi, 30238505, Kido, Ryo, Akizawa, Tadao, Fukagawa, Masafumi, Onishi, Yoshihiro, Yamaguchi, Takuhiro, and Fukuhara, Shunichi

Abstract

Bachground: Does the use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers individually or as a combination confer a survival benefit in hemodialysis patients? The answer to this question is yet unclear. Methods: We performed a case-cohort study using data from the Mineral and Bone Disorder Outcomes Study for Japanese CKD stage 5D patients (MBD-5D), a 3-year multicenter prospective case-cohort study, including 8, 229 hemodialysis patients registered from 86 facilities in Japan. All patients had secondary hyperparathyroidism, a condition defined as a parathyroid hormone level ≥180 pg/mL and/or receiving vitamin D receptor activators. We compared all-cause mortality rates between those receiving ACEI, ARB, and their combination and non-users with interaction testing. We used marginal structural Poisson regression (causal model) to estimate the causal effect and interaction adjusted for possible time-dependent confounding. Cardiovascular mortality was also evaluated. Results: Among 3, 762 randomly sampled subcohort patients, those taking ACEI, ARB, and their combination at baseline accounted for 4.0, 31.6, and 3.8%, respectively. Over 3 years, 1, 226 all-cause and 462 cardiovascular deaths occurred. Compared to non-users, ARB-alone users had a lower all-cause mortality rate (adjusted incident rate ratio [aIRR] 0.62, 95% CI 0.50–0.76), whereas ACEI-alone users showed a statistically similar rate (aIRR 1.01, 95% CI 0.57–1.77). On the contrary, combination users had a greater mortality rate (aIRR 2.56, 95% CI 1.22–5.37), showing significant interaction (p = 0.03). Analysis for cardiovascular mortality showed similar results. Conclusion: Among hemodialysis patients with secondary hyperparathyroidism, unlike ACEI use, ARB use was associated with greater survival than non-use. Conversely, combination use was associated with greater mortality. Controlled trials are warranted to verify the causality factors of these associations.

Published
2018

15. SP331CHRONIC KIDNEY DISEASE AND THE ASSOCIATION OF SELF-ASSESSED LIFESTYLE BEHAVIORS WITH MORTALITY IN A LARGE JAPANESE GENERAL POPULATION

Author

Furusawa, Ayami, primary, Kido, Ryo, additional, Murasawa, Masaru, additional, Uchida, Daisuke, additional, Fujimoto, Shouichi, additional, Iseki, Kunitoshi, additional, Moriyama, Toshiki, additional, Yamagata, Kunihiro, additional, Tsuruya, Kazuhiko, additional, Konta, Tsuneo, additional, Narita, Ichiei, additional, Kondo, Masahide, additional, Kasahara, Masato, additional, Asahi, Koichi, additional, Watanabe, Tsuyoshi, additional, Shibagaki, Yugo, additional, and Kawarazaki, Hiroo, additional

Published
2017
Full Text
View/download PDF

21. Interactive Effectiveness of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers or Their Combination on Survival of Hemodialysis Patients.

Author

Kido, Ryo, Akizawa, Tadao, Fukagawa, Masafumi, Onishi, Yoshihiro, Yamaguchi, Takuhiro, and Fukuhara, Shunichi

Subjects
HEMODIALYSIS, ANGIOTENSIN converting enzyme, ANGIOTENSIN receptors, SURVIVAL analysis (Biometry), VITAMIN D receptors
Abstract

Background: Does the use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers individually or as a combination confer a survival benefit in hemodialysis patients? The answer to this question is yet unclear.Methods: We performed a case-cohort study using data from the Mineral and Bone Disorder Outcomes Study for Japanese CKD stage 5D patients (MBD-5D), a 3-year multicenter prospective case-cohort study, including 8,229 hemodialysis patients registered from 86 facilities in Japan. All patients had secondary hyperparathyroidism, a condition defined as a parathyroid hormone level ≥180 pg/mL and/or receiving vitamin D receptor activators. We compared all-cause mortality rates between those receiving ACEI, ARB, and their combination and non-users with interaction testing. We used marginal structural Poisson regression (causal model) to estimate the causal effect and interaction adjusted for possible time-dependent confounding. Cardiovascular mortality was also evaluated.Results: Among 3,762 randomly sampled subcohort patients, those taking ACEI, ARB, and their combination at baseline accounted for 4.0, 31.6, and 3.8%, respectively. Over 3 years, 1,226 all-cause and 462 cardiovascular deaths occurred. Compared to non-users, ARB-alone users had a lower all-cause mortality rate (adjusted incident rate ratio [aIRR] 0.62, 95% CI 0.50-0.76), whereas ACEI-alone users showed a statistically similar rate (aIRR 1.01, 95% CI 0.57-1.77). On the contrary, combination users had a greater mortality rate (aIRR 2.56, 95% CI 1.22-5.37), showing significant interaction (p = 0.03). Analysis for cardiovascular mortality showed similar results.Conclusion: Among hemodialysis patients with secondary hyperparathyroidism, unlike ACEI use, ARB use was associated with greater survival than non-use. Conversely, combination use was associated with greater mortality. Controlled trials are warranted to verify the causality factors of these associations. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

39. Cloning and recombinant expression of rat and human kynureninase

Author

Toma, Salvatore, primary, Nakamura, Masayuki, additional, Toné, Shigenobu, additional, Okuno, Etsuo, additional, Kido, Ryo, additional, Breton, Jerome, additional, Avanzi, Nilla, additional, Cozzi, Liviana, additional, Speciale, Carmela, additional, Mostardini, Marina, additional, Gatti, Silvia, additional, and Benatti, Luca, additional

Published
1997
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results